Drug Trial Radar · NCT05083260
NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa
Last checked: Nov 19, 2026Latest source record: Feb 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Jan 4, 2022
Primary completion
Nov 21, 2022
Study completion Jan 4, 2023
Sponsor
- Lead sponsor
- BioVie Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A 28-day phase 2a, double-blind, placebo-controlled (1:1), multi-center study of 20 mg NE3107, twice daily of safety, potential drug-drug interactions, and MDS-UPDRS defined activity in patients with Parkinson's disease . Study will enroll 40 patients that are currently taking immediate release levodopa/ carbidopa (IRLC) and have a practically defined early morning off-state for IRLC. Day one- baseline UPDRS and IRLC PK sampling; day 2- start NE3107 dosing, assess UPDRS during onset and NE3107 PK sampling, rescue meds as needed after 4 hours; day 3 and 14- NE3107 + IRLC UPDRS assessment and PK sampling; day 28- NE3107 + IRLC UPDRS assessments. Optional overnight stays in clinic prior to Day 1-3, 14, and 28.
Conditions
- Parkinson Disease
Interventions
NE3107Drug
NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Parkinson's disease
placeboDrug
Hard gelatin capsule containing only common excipients for oral formulations
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline (day 1) in Motor disease society- Unified Parkinson's disease rating scale Part III total score for the patient in the "off-state" (without L-dopa for previous eight hours)Time frame: measured on day 1, 2, 3, 14, and 28
- Change from baseline in the length of time during which L-dopa therapy is ineffective in reducing motor symptoms of disease (OFF time)Time frame: off time will be measured/recorded every day from day 2 to day 27
- Change from baseline in average Motor disease society- Unified Parkinson's disease rating scale Part III total score measured over the course of 8 hours after taking L-dopa and/or NE3107Time frame: measured on day 1, 2, 3, 14, and 28
- Motor disease society- Unified Parkinson's disease rating scale Part I total scoreTime frame: measured on day 1, 2, 3, 14, and 28
- Motor disease society- Unified Parkinson's disease rating scale Part 2 total scoreTime frame: measured on day 1, 2, 3, 14, and 28
- Change from baseline in the length of time during which L-dopa-like effects are felt by the patientTime frame: baseline and day 1, 2, 3, 14, and 28
- change from baseline in L-dopa induced dyskinesia measured with the abnormal involuntary movement scale (AIMS)Time frame: AIMS will be measured during the 8 hour period of observation on Day 1, 2, 3, 14, and 28
- change from baseline in time to onset of L-dopa-like activityTime frame: measured on Day 1, 2, 3, 14, and 28
- Change from baseline in Non-Motor Symptom Assessment Scale for Parkinson Disease (NMSS)Time frame: Measured on Day 1, 2, 3, 14, and 28
- change in area under the levodopa plasma concentration vs. time curve when administered alone compared to being co-administered with NE3107Time frame: Blood samples will be collected on Day 1, 2, 3, and 14
- Change in the maximum plasma concentration (Cmax) of levodopa when administered alone compared to being co-administered with NE3107.Time frame: Blood samples will be collected on Day 1, 2, 3, and 14
- The area under the NE3107 plasma concentration vs. time curve when administered alone compared to being co-administered withTime frame: Blood samples will be collected on Day 2, 3, and 14
- Change in the maximum plasma concentration (Cmax) of NE3107 when administered alone compared to being co-administered with L-dopaTime frame: Blood samples will be collected on Day 2, 3, and 14
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Rocky Mountain Movement Disorders Center
Englewood, Colorado
Parkinson's Disease & Movement Disorders Center Of Boca Raton
Boca Raton, Florida
Velocity
Hallandale, Florida
Charter Research
Lady Lake, Florida
Premier Clinical Research Institute
Miami, Florida
First Excellent Research Group
Miami, Florida
First Excellent Research
Miami, Florida
EZY Medical Research
Miami, Florida
Charter Research
Winter Park, Florida
Quest Research Institute
Farmington Hills, Michigan
New York Neurology Associates
New York, New York
Duke University
Durham, North Carolina
M3 Wake Research
Raleigh, North Carolina
University of Toledo
Toledo, Ohio
Texas Institute for Neurological Disorders
Sherman, Texas
Inland Northwest Research
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.